Literature DB >> 20544397

Impact of resection for primary colorectal cancer on outcomes in patients with synchronous colorectal liver metastases.

Jung Wook Huh1, Chol Kyoon Cho, Hyeong Rok Kim, Young Jin Kim.   

Abstract

PURPOSE: This study was designed to evaluate the impact of resection for primary colorectal cancer on oncologic outcomes in patients with synchronous colorectal liver metastases.
METHODS: A retrospective analysis was performed on 91 consecutive patients with synchronous colorectal liver metastases who underwent resection of the primary colorectal cancer between December 1999 and December 2007. Of the 91 patients, 54 (59.3%) also underwent complete (R0) resection for liver metastases, and 84 (92.3%) received postoperative chemotherapy. The oncologic outcomes and prognostic factors were analyzed.
RESULTS: Operative mortality was 1.1%, and morbidity was 37.4%. The 3- and 5-year overall survival rates were 44.5% and 26.8%, respectively. A multivariate analysis revealed that residual disease after surgery (non-R0 resection; p = 0.003), lymph node metastasis of the primary tumor (p = 0.015), and no postoperative chemotherapy (p = 0.001) were independent prognostic factors for poor survival. Independent predictors of an inability to achieve a complete resection were the presence of three or more liver metastases and the presence of extrahepatic disease at exploration. Significant differences in survival existed among the three risk stratification groups (no-, low-, and high-risk groups; p < 0.001).
CONCLUSIONS: The inability to safely render the liver and colon microscopically free of disease should cause a surgeon to reconsider synchronous colectomy and hepatectomy. A multidisciplinary approach that combines both complete resection of synchronous colorectal liver metastases and postoperative chemotherapy may achieve improved survival in patients with synchronous colorectal liver metastases.

Entities:  

Mesh:

Year:  2010        PMID: 20544397     DOI: 10.1007/s11605-010-1250-7

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  31 in total

1.  How aggressive should we be in patients with stage IV colorectal cancer?

Authors:  Li-Jen Kuo; Shuh-Yan Leu; Mei-Ching Liu; James Jer-Min Jian; Skye Hongiun Cheng; Chung-Ming Chen
Journal:  Dis Colon Rectum       Date:  2003-12       Impact factor: 4.585

2.  Initial presentation with stage IV colorectal cancer: how aggressive should we be?

Authors:  S A Rosen; J F Buell; A Yoshida; S Kazsuba; R Hurst; F Michelassi; J M Millis; M C Posner
Journal:  Arch Surg       Date:  2000-05

3.  Palliative operations for colorectal cancer.

Authors:  J Mäkelä; K Haukipuro; S Laitinen; M I Kairaluoma
Journal:  Dis Colon Rectum       Date:  1990-10       Impact factor: 4.585

4.  Clinicopathological features and prognosis in resectable synchronous and metachronous colorectal liver metastasis.

Authors:  Ming-Shian Tsai; Yen-Hao Su; Ming-Chih Ho; Jin-Tung Liang; Tzu-Ping Chen; Hong-Shiee Lai; Po-Huang Lee
Journal:  Ann Surg Oncol       Date:  2006-11-14       Impact factor: 5.344

5.  Treatment strategy for patients with colorectal cancer and synchronous irresectable liver metastases.

Authors:  S Benoist; K Pautrat; E Mitry; P Rougier; C Penna; B Nordlinger
Journal:  Br J Surg       Date:  2005-09       Impact factor: 6.939

6.  Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients.

Authors:  Myrddin Rees; Paris P Tekkis; Fenella K S Welsh; Thomas O'Rourke; Timothy G John
Journal:  Ann Surg       Date:  2008-01       Impact factor: 12.969

7.  Synchronous hepatic metastases from colon cancer: changing treatment strategies and results of surgical intervention.

Authors:  Bridget N Fahy; Michael D'Angelica; Ronald P DeMatteo; Leslie H Blumgart; Martin R Weiser; Irina Ostrovnaya; Mithat Gonen; William R Jarnagin
Journal:  Ann Surg Oncol       Date:  2008-12-03       Impact factor: 5.344

8.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

9.  Results of R0 resection for colorectal liver metastases associated with extrahepatic disease.

Authors:  Dominique Elias; Lucas Sideris; Marc Pocard; Jean-Francois Ouellet; Valérie Boige; Philippe Lasser; Jean-Pierre Pignon; Michel Ducreux
Journal:  Ann Surg Oncol       Date:  2004-03       Impact factor: 5.344

10.  Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases.

Authors:  N C Tebbutt; A R Norman; D Cunningham; M E Hill; D Tait; J Oates; S Livingston; J Andreyev
Journal:  Gut       Date:  2003-04       Impact factor: 23.059

View more
  10 in total

1.  Identification of patients likely to benefit from metastasectomy in stage IV colorectal cancer.

Authors:  Manabu Shimomura; Masazumi Okajima; Takao Hinoi; Hiroyuki Egi; Yuji Takakura; Yasuo Kawaguchi; Masakazu Tokunaga; Tomohiro Adachi; Hirotaka Tashiro; Hideki Ohdan
Journal:  Int J Colorectal Dis       Date:  2012-03-10       Impact factor: 2.571

Review 2.  [Oligometastasized stage IV colorectal cancer : Surgical resection and local ablative procedures].

Authors:  M Binnebösel; P Bruners; C D Klink; C Kuhl; U P Neumann
Journal:  Chirurg       Date:  2016-05       Impact factor: 0.955

3.  Prognostic factors associated with primary cancer in curatively resected stage IV colorectal cancer.

Authors:  Jung Wook Huh; Woo Yong Lee; Yoon Ah Park; Yong Beom Cho; Seong Hyeon Yun; Hee Cheol Kim; Ho-Kyung Chun
Journal:  J Cancer Res Clin Oncol       Date:  2014-01-12       Impact factor: 4.553

4.  Comparison of laparoscopic and open colorectal resections for patients undergoing simultaneous R0 resection for liver metastases.

Authors:  Jung Wook Huh; Yang Seok Koh; Hyeong Rok Kim; Chol Kyoon Cho; Young Jin Kim
Journal:  Surg Endosc       Date:  2010-06-12       Impact factor: 4.584

5.  Locoregional surgical and interventional therapies for advanced colorectal cancer liver metastases: expert consensus statements.

Authors:  Eddie K Abdalla; Todd W Bauer; Yun S Chun; Michael D'Angelica; David A Kooby; William R Jarnagin
Journal:  HPB (Oxford)       Date:  2013-02       Impact factor: 3.647

Review 6.  Liver-directed therapies in metastatic colorectal cancer.

Authors:  Margaret E Clark; Richard R Smith
Journal:  J Gastrointest Oncol       Date:  2014-10

Review 7.  [Oligometastasized colorectal cancer-modern treatment strategies].

Authors:  M Binnebösel; A Lambertz; K Dejong; U P Neumann
Journal:  Chirurg       Date:  2018-07       Impact factor: 0.955

8.  Downregulation of myosin VI reduced cell growth and increased apoptosis in human colorectal cancer.

Authors:  Weiqiang You; Gewen Tan; Nengquan Sheng; Jianfeng Gong; Jun Yan; Di Chen; Huizhen Zhang; Zhigang Wang
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2016-04-03       Impact factor: 3.848

9.  Clinical practice guidelines for the management of metastatic colorectal cancer: a consensus statement of the Hellenic Society of Medical Oncologists (HeSMO).

Authors:  Christos Dervenis; Evaghelos Xynos; George Sotiropoulos; Nikolaos Gouvas; Ioannis Boukovinas; Christos Agalianos; Nikolaos Androulakis; Athanasios Athanasiadis; Christos Christodoulou; Evangelia Chrysou; Christos Emmanouilidis; Panagiotis Georgiou; Niki Karachaliou; Ourania Katopodi; Panteleimon Kountourakis; Ioannis Kyriazanos; Thomas Makatsoris; Pavlos Papakostas; Demetris Papamichael; George Pechlivanides; Georgios Pentheroudakis; Ioannis Pilpilidis; Joseph Sgouros; Paris Tekkis; Charina Triantopoulou; Maria Tzardi; Vassilis Vassiliou; Louiza Vini; Spyridon Xynogalos; Nikolaos Ziras; John Souglakos
Journal:  Ann Gastroenterol       Date:  2016-06-03

10.  Hsa-miR-574-5p negatively regulates MACC-1 expression to suppress colorectal cancer liver metastasis.

Authors:  Zhe Cui; Jian Tang; Jinxian Chen; Zheng Wang
Journal:  Cancer Cell Int       Date:  2014-06-07       Impact factor: 5.722

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.